Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Rheumatology and Therapy
Subjects:
CLK/DYRK inhibitor
Disease-modifying osteoarthritis drug (DMOAD)
Knee osteoarthritis
Lorecivivint
Osteoarthritis
Safety
Online Access:https://doi.org/10.1007/s40744-024-00731-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-024-00731-9

Similar Items